Loading...
Orexo AB (publ)
ORXOF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$2.02
$0.00(0.00%)
Orexo AB (publ) (ORXOF) Financial Performance & Income Statement Overview
Review Orexo AB (publ)’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-7.64%
↓ 7.64%
Operating Income Growth
-28.13%
↓ 28.13%
Net Income Growth
-58.22%
↓ 58.22%
Operating Cash Flow Growth
65.68%
↑ 65.68%
Operating Margin
-23.57%
↓ 23.57%
Gross Margin
86.70%
↑ 86.70%
Net Profit Margin
-35.16%
↓ 35.16%
ROE
288.92%
↑ 288.92%
ROIC
-43.51%
↓ 43.51%
Orexo AB (publ) (ORXOF) Income Statement & Financial Overview
Review Orexo AB (publ)'s (ORXOF) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $146.20M | $160.30M | $136.50M | $154.00M |
| Cost of Revenue | $20.70M | $22.30M | $20.10M | $37.10M |
| Gross Profit | $125.50M | $138.00M | $116.40M | $137.70M |
| Gross Profit Ratio | $0.86 | $0.86 | $0.85 | $0.89 |
| R&D Expenses | $51.60M | $162.90M | $56.20M | $64.30M |
| SG&A Expenses | $73.50M | $104.40M | $79.40M | $94.40M |
| Operating Expenses | $130.70M | $236.00M | $138.10M | $153.50M |
| Total Costs & Expenses | $151.40M | $258.30M | $158.20M | $169.80M |
| Interest Income | $0.00 | $600000.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $12.40M | $15.40M | $21.50M |
| Depreciation & Amortization | $11.10M | $126.80M | $21.00M | $20.80M |
| EBITDA | $5.90M | $32.90M | -$700000.00 | $5.00M |
| EBITDA Ratio | $0.04 | $0.21 | -$0.005 | $0.03 |
| Operating Income | -$5.20M | -$98.00M | -$21.70M | -$15.80M |
| Operating Income Ratio | -$0.04 | -$0.61 | -$0.16 | -$0.10 |
| Other Income/Expenses (Net) | -$14.10M | -$8.30M | -$15.40M | -$21.50M |
| Income Before Tax | -$19.30M | -$106.30M | -$37.10M | -$37.30M |
| Income Before Tax Ratio | -$0.13 | -$0.66 | -$0.27 | -$0.24 |
| Income Tax Expense | -$3.30M | $9.90M | $4.80M | -$1.40M |
| Net Income | -$15.90M | -$116.20M | -$41.90M | -$35.90M |
| Net Income Ratio | -$0.11 | -$0.72 | -$0.31 | -$0.23 |
| EPS | -$0.46 | -$3.37 | -$1.21 | -$1.04 |
| Diluted EPS | -$0.46 | -$3.37 | -$1.21 | -$1.04 |
| Weighted Avg Shares Outstanding | $34.51M | $34.48M | $34.51M | $34.50M |
| Weighted Avg Shares Outstanding (Diluted) | $34.51M | $34.48M | $34.51M | $34.50M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan